WHAT IS CLAIMED IS:

1.. A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where $\mathbf{R_1}$ is independently H or lower alkyl of 1 to 6 carbons;

$\mathbf{R_2}$ and $\mathbf{R_3}$ are independently H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;

n is 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl, and

B is COOH, a pharmaceutically acceptable salt thereof, $CONR_6R_7$ or $COOR_8$ where $\mathbf{R_6}$ and $\mathbf{R_7}$ independently are hydrogen or an alkyl group of 1 to 6 carbons and $\mathbf{R_8}$ is alkyl of 1 to 6 carbons,

said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal.

2. A pharmaceutical composition in accordance with Claim 1 wherein the chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal is interferon.

3. A pharmaceutical composition in accordance with Claim 2 adapted for the treatment of breast cancer.

4. A pharmaceutical composition in accordance with Claim 2 adapted for the treatment of leukemia.

5. A pharmaceutical composition in accordance with Claim 1 wherein the compound has the formula



where $\mathbf{R_1}$ is H or methyl, $\mathbf{R_3}$ is H or methyl, and $\mathbf{R^*_8}$ is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.

6. A pharmaceutical composition in accordance with Claim 5 wherein the chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal is interferon.

7. A pharmaceutical composition in accordance with Claim 6 adapted for the treatment of breast cancer.

8. A pharmaceutical composition in accordance with Claim 5 adapted for the treatment of leukemia.

9. A pharmaceutical composition in accordance with Claim 1 wherein the compound has the formula



where $\mathbf{R_8}$ is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.

10. A pharmaceutical composition in accordance with Claim 9 wherein the chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal is interferon.

11. A pharmaceutical composition in accordance with Claim 10 adapted for the treatment of breast cancer.

12. A pharmaceutical composition in accordance with Claim 10 adapted for the treatment of leukemia.

13. A pharmaceutical composition in accordance with Claim 9 where $\mathbf{R_8}$ is ethyl.

14. A method of treating a malignant disease or condition in a mammal in need of such treatment, the method comprising the steps of:

administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where R_1 is independently H or lower alkyl of 1 to 6 carbons;

R_2 and R_3 are independently H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;

n is 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl; oxazolyl, thiazolyl, or imidazolyl;

B is COOH, a pharmaceutically acceptable salt thereof, $CONR_6R_7$ or $COOR_8$ where R_6 and R_7 independently are hydrogen or an alkyl group of 1 to 6 carbons and R_8 is alkyl of 1 to 6 carbons, and

co-administering to said mammal with said compound another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal.

15. A method in accordance with Claim 14 where the chemotherapeutic agent is interferon.

16. A method in accordance with Claim 15 where the chemotherapeutic agent is human recombinant interferon α, human recombinant interferon β, or human recombinant interferon γ.

17. A method in accordance with Claim 16 where the malignant disease or condition treated is breast cancer or leukemia.

18. A method in accordance with Claim 17 where the malignant disease or condition treated is acute myeloid leukemia.

19. A method in accordance with Claim 14 wherein the compound has the formula



where $\mathbf{R_1}$ is H or methyl, $\mathbf{R_3}$ is H or methyl, and $\mathbf{R^*_8}$ is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.

20. A method in accordance with Claim 19 where the chemotherapeutic agent is interferon.

21. A method in accordance with Claim 20 where the chemotherapeutic agent is human recombinant interferon α, human recombinant interferon β, or human recombinant interferon γ.

22. A method in accordance with Claim 21 where the malignant disease or condition treated is breast cancer or leukemia.

23. A method in accordance with Claim 21 where the malignant disease or condition treated is acute myeloid leukemia.

24. A method in accordance with Claim 14 wherein the compound has the formula



where R_8 is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.

25. A method in accordance with Claim 24 where R_8 is ethyl.

26. A method in accordance with Claim 25 where the chemotherapeutic agent is interferon.

27. A method in accordance with Claim 26 where the chemotherapeutic agent is human recombinant interferon α, human recombinant interferon β, or human recombinant interferon γ.

28. A method in accordance with Claim 27 where the malignant disease or condition treated is breast cancer or leukemia.

29. A method in accordance with Claim 27 where the malignant disease or condition treated is acute myeloid leukemia.

30. A method in accordance with any of the Claims 24 through 29 wherein a daily dose of approximately 50 mg to 500 mg of the compound is administered to the mammal.

Add B3